Cargando…
Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...
Autores principales: | Maier, Smaranda, Simu, Mihaela, Hutanu, Adina, Barcutean, Laura, Voidazan, Septimiu, Bajko, Zoltan, Motataianu, Anca, Lata, Irina, Balasa, Rodica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692182/ https://www.ncbi.nlm.nih.gov/pubmed/33143271 http://dx.doi.org/10.3390/brainsci10110802 |
Ejemplares similares
-
Autonomic and Somatic Nerve Functions in Type 2 Diabetes Mellitus Patients: Electrophysiological Aspects
por: Motataianu, Anca, et al.
Publicado: (2021) -
The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients
por: Romaniuc, Andreea, et al.
Publicado: (2020) -
Predictors of Depression in Caucasian Patients with Amyotrophic Lateral Sclerosis in Romania
por: Anca, Motataianu, et al.
Publicado: (2020) -
Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients
por: Moţăţăianu, Anca, et al.
Publicado: (2018) -
Sociodemographic and Clinical Determinants of Fatigue in Multiple Sclerosis
por: Maier, Smaranda, et al.
Publicado: (2023)